News FDA clears subcutaneous Keytruda in a boost to MSD MSD's Keytruda will soon be available as a subcutaneous injection, improving convenience for patients and defending it from a looming patent loss.
News Imfinzi becomes first NHS drug for aggressive lung cancer AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.
News J&J claims FDA okay for bladder cancer drug TAR-200 Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.
News Lilly offers AI discovery models to biotech partners Eli Lilly is offering AI-powered drug discovery models developed at a cost of around $1 billion to biotech companies for free.
News Lilly eyes earlier use of blood cancer drug Jaypirca Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.
News NHS trust league tables arrive in UK health shakeup League tables for NHS trusts will end the postcode lottery of care, says the government, but not all are convinced.
News After internal setbacks, Pfizer buys obesity player Metsera Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.